This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
DB Allison , KR Fontaine , M Heo , JL Mentore , (1999). The distribution of body mass index among individuals with and without schizophrenia. Journal Clinical Psychiatry 60, 215–220.
NC Andreasen (1995). Symptoms, signs, and diagnosis of schizophrenia. Lancet 346, 477–481.
TR Barnes (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672–676.
Y Bloch , S Mendlovic , S Strupinsky , A Altshuler , (2001). Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? Journal Clinical Psychiatry 62, 855–859.
M Byerly , R Fisher , K Whatley , R Holland , (2005). A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 133, 129–133.
M Davidson , R Emsley , M Kramer , L Ford , (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 93, 117–130.
D Hough , JP Lindenmayer , S Gopal , R Melkote , (2009). Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 33, 1022–1031.
DA Johnson , G Pasterski , JM Ludlow , K Street , (1983). The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatrica Scandinavica 67, 339–352.
J Kane , F Canas , M Kramer , L Ford , (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research 90, 147–161.
SR Kay , A Fiszbein , LA Opler (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261–276.
SJ Keith , JM Kane (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal Clinical Psychiatry 64, 1308–1315.
M Kramer , G Simpson , V Maciulis , S Kushner , (2007). Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Journal Clinical Psychopharmacology 27, 6–14.
TP Laughren (2001). The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. European Psychiatry 16, 418–423.
S Leucht , JM Kane , W Kissling , J Hamann , (2005). What does the PANSS mean? Schizophrenia Research 79, 231–238.
JP Lindenmayer , R Bernstein-Hyman , S Grochowski (1994). A new five factor model of schizophrenia. Psychiatry Quarterly 65, 299–322.
JP Lindenmayer , K Jarboe , CA Bossie , Y Zhu , (2005). Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. International Clinical Psychopharmacology 20, 213–221.
SR Marder , JM Davis , G Chouinard (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal Clinical Psychiatry 58, 538–546.
SR Marder , M Kramer , L Ford , E Eerdekens , (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry 62, 1363–1370.
HA Nasrallah (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatrica Scandinavica 115, 260–267.
D Robinson , MG Woerner , JM Alvir , R Bilder , (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives General Psychiatry 56, 241–247.
A Sagie , MG Larson , RJ Goldberg , JR Bengtson , (1992). An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). American Journal Cardiology 70, 797–801.
MN Samtani , A Vermeulen , K Stuyckens (2009). Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clinical Pharmacokinetics 48, 585–600.
RJ Wyatt (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 17, 325–351.